Dana provides advisory services to clients within the healthcare industry, as well as defends clients in government investigations and litigation. Dana offers guidance on a broad spectrum of statutory and regulatory compliance issues, including corporate practice of medicine, privacy, licensure, telehealth, antitrust, food and drug law, pharmacy operations, enrollment and reimbursement, and fraud and abuse.
Dana has played a crucial role in successfully resolving a Department of Justice (DOJ) investigation into a medical device company. This involved various responsibilities, such as preparing presentations for the DOJ, conducting research and analysis on legal matters related to privilege, healthcare fraud, and bankruptcy, drafting memoranda and claw-back agreements, and contributing to strategic settlement negotiations.
In addition, Dana participated in the defense of a national pharmacy chain involved in opioid-related multidistrict litigation (MDL) and state proceedings, where his healthcare expertise was leveraged to assist in preparation of expert cross-examination outlines, the development of FRE 702/Daubert challenges to opposing experts, and to conduct regulatory analysis related to the case.
Additionally, Dana has spearheaded the qualification efforts in multiple states for a telehealth client. Dana also facilitated the transfer of ownership of the client's professional corporations and the incorporation of an additional entity. Furthermore, he has authored client alerts, commentaries, presentations, and whitepapers addressing key developments and issues in the healthcare and anti-human trafficking arenas.
Prior to law school, Dana spent several years working for a healthcare and health policy research institute based out of Boston's largest academic institution.